Aim To analyze the polymorphism of the CD147 gene 3′UTR rs8259 in patients with ST-segment elevation myocardial infarction （STEMI）, and to study the relation between plasma levels, genotype of CD147 and STEMI.Methods The polymorphism of CD147 was detected by polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP） and DNA sequencing method in 162 STEMI patients and 328 healthy persons. The plasma level of CD147 was determined by enzyme-linked immunosorbent assay （ELISA）. Results STEMI group （4.18 ± 0.95 pg/L） showed significantly higher plasma level of CD147 than control group （2.55 ± 0.29 pg/L） （P<0.01）. There was a significant difference in frequencies of alleles and genotypes in 3′UTR rs8259 of CD147 with three genotypes AA, AT and TT existed （P<0.05）. Logistic regression analysis for adjusting other risk factors displayed that AT genotypes （OR0.346, 95%CI: 0.210～0.569,P<0.05） and TT genotypes （OR0.107, 95%CI: 0.046～0.251, P<0.05） can decrease the relative risk of STEMI. Allele T carriers had low onset risk for STEMI （OR0.543, 95%CI: 0.404～0.730, P<0.05）, and allele A carriers had high risk for STEMI （OR1.841, 95%CI: 1.370～2.464, P<0.05）. The plasma level of CD147 was the highest in AA genotype （P<0.05）. Conclusions CD147 gene 3′UTR rs8259 allele A is probably the susceptible gene of STEMI. AA genotype can be at increased risk of STEMI due to enhancing the CD147 expression and allele T may be protective for STEMI.